Year 2022 / Volume 114 / Number 2
Original
Thiopurine adherence: a high prevalence with low impact on UC outcomes

76-82

DOI: 10.17235/reed.2021.7630/2020

Concepción Gómez-Medina, María Capilla-Lozano, María Pilar Ballester-Ferré, David Martí-Aguado, Ana Crespo, Marta Maia Bosca-Watts, Pablo Navarro-Cortés, Rosario Antón, Isabel Pascual-Moreno, Joan Tosca Cuquerella, Miguel Mínguez Pérez,

Abstract
Introduction: thiopurines are used as maintenance therapy in patients with ulcerative colitis (UC). There are contradictory results regarding the relationship between adherence to treatment and risk of relapse. Objectives: to quantify and evaluate the trends in thiopurine prescription rates, and to determine the impact and risk factors of non-adherence. Methods: analytical, observational, retrospective study of UC patients taking thiopurines included in the ENEIDA single-center registry from October 2017 to October 2019. Adult patients in clinical remission at the beginning of the study on thiopurines maintenance treatment for at least 6 months before recruitment were included. Adherence was evaluated with an electronic pharmaceutical prescription system. Adherence was considered when 80 % or more of the prescribed medication was dispensed at the pharmacy. Kaplan-Meier curves and a regression model were used to examine year-to-year treatment dispensation, and to identify factors associated with non-adherence. Results: a total of 41 patients were included, of whom 71 % were males with a mean age of 44 (14), and 26.8 % were concomitantly managed with biological therapy. Overall, 22 % were non-adherent to thiopurines. No predictive factors of non-adherence were identified. Adherence rate did not correlate with disease activity during two years of follow-up (OR 1.6; 95 % CI = 0.3-9.1). Left-sided colitis and concomitant biological treatment were related with disease relapse (p ≤ 0.01). Conclusion: adherence to thiopurines in UC patients is high (78 %). Non-adherence is not related to clinical or pharmacological factors. Adherence rate was not associated with disease activity.
Share Button
New comment
Comments
No comments for this article
References
1. Robinson A. Review article: improving adherence to medication in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2008;27(1):9-14.
2. Trindade AJ, Ehrlich A, Kornbluth A, et al. Are your patients taking their medicine? Validation of a new adherence scale in patients with inflammatory bowel disease and comparison with physician perception of adherence. Inflamm Bowel Dis 2011;17(2):599-604.
3. Kane S, Huo D, Aikens J, et al. Medication Nonadherence and the Outcomes of Patients with Quiescent Ulcerative Colitis. Am J Med 2003;114(1):39-43.
4. Kane SV. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2006;23(5):577-85.
5. Gilissen LPL, Wong DR, Engels LGJB, et al. Therapeutic drug monitoring of thiopurine metabolites in adult thiopurine tolerant IBD patients on maintenance therapy. J Crohns Colitis 2012;6(6):698-707.
6. Bokemeyer B, Teml A, Roggel C, et al. Adherence to thiopurine treatment in out-patients with Crohn’s disease. Aliment Pharmacol Ther 2007;26(2):217-25.
7. Mantzaris GJ, Roussos A, Kalantzis C, et al. How Adherent to Treatment with Azathioprine Are Patients with Crohnʼs Disease in Long-term Remission? Inflamm Bowel Dis 2007;13(4):446-50.
8. Ediger JP, Walker JR, Graff L, et al. Predictors of Medication Adherence in Inflammatory Bowel Disease. Am J Gastroenterol 2007;102(7):1417-26.
9. Hommel KA, Davis CM, Baldassano RN. Medication adherence and quality of life in pediatric inflammatory bowel disease. J Pediatr Psychol 2008;33(8):867-74.
10. LeLeiko NS, Lobato D, Hagin S, et al. 6-Thioguanine Levels in Pediatric IBD Patients. Inflamm Bowel Dis 2013;19(12):2652-8.
11. Kamperidis N, Goodhand JR, Chowdhury FA, et al. Factors Associated With Nonadherence to Thiopurines in Adolescent and Adult Patients With Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 2012;54(5):685-9.
12. Campos S, Portela F, Sousa P, et al. Inflammatory bowel disease: adherence to immunomodulators in a biological therapy era. Eur J Gastroenterol Hepatol 2016;28(11):1313-9.
13. D’incà R, Bertomoro P, Mazzocco K, et al. Risk factors for non-adherence to medication in inflammatory bowel disease patients. Aliment Pharmacol Ther 2007;27(2):166-72.
14. Osterberg L, Blaschke T. Adherence to Medication. N Engl J Med 2005;353(5):487-97.
15. Oliva-Hemker MM, Abadom V, Cuffari C, et al. Nonadherence with Thiopurine Immunomodulator and Mesalamine Medications in Children with Crohn Disease. J Pediatr Gastroenterol Nutr 2007;44(2):180-4.
16. Hommel KA, Davis CM, Baldassano RN. Objective versus subjective assessment of oral medication adherence in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2009;15(4):589-93.
17. Hommel KA, Hente EA, Odell S, et al. Evaluation of a group-based behavioral intervention to promote adherence in adolescents with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2012;24(1):64-9.
18. LeLeiko NS, Lobato D, Hagin S, et al. Rates and Predictors of Oral Medication Adherence in Pediatric Patients with IBD. Inflamm Bowel Dis 2013;19(4):832-9.
19. de Castro ML, Sanromán L, Martín A, et al. Assessing medication adherence in inflammatory bowel diseases. A comparison between a self-administered scale and a pharmacy refill index. Rev Esp Enferm Dig 2017;109(8):542-51.
20. Selinger CP, Ochieng AO, George V, et al. The Accuracy of Adherence Self-report Scales in Patients on Thiopurines for Inflammatory Bowel Disease: A Comparison With Drug Metabolite Levels and Medication Possession Ratios. Inflamm Bowel Dis 2018;0(0):1-6.
21. Lopez A, Billioud V, Peyrin-Biroulet C, et al. Adherence to Anti-TNF Therapy in Inflammatory Bowel Diseases. Inflamm Bowel Dis 2013;19(7):1528-33.
22. Kane S, Becker B, Harmsen WS, et al. Use of a screening tool to determine nonadherent behavior in inflammatory bowel disease. Am J Gastroenterol 2012;107(2):154-60.
23. Bond CA, Monson R. Sustained improvement in drug documentation, compliance, and disease control. A four-year analysis of an ambulatory care model. Arch Intern Med 1984;144(6):1159-62.
24. Steiner JF, Koepsell TD, Fihn SD, et al. A general method of compliance assessment using centralized pharmacy records. Med Care 1988;26(8):814-23.
25. Lenti MV, Selinger CP. Medication non-adherence in adult patients affected by inflammatory bowel disease: a critical review and update of the determining factors, consequences and possible interventions, Expert Review of Gastroenterology & Hepatology 2017;11(3):215-26.
26. Stange EF, Travis SPL, Vermeire S, et al. European evidence-based consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohn’s Colitis 2008;2:1-23.
27. Silverberg M, Satsangi J, Ahmad T, et al. Toward and integrated clinical, molecular, and serological classification of inflammatory bowel disease: re-port or a working party of the Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005;19(Suppl A):5A-36A.
28. World Health Organization. International classification of diseases: [‎9th]‎ ninth revision, basic tabulation list with alphabetic index. World Health Organization; 1978. Available from: https://apps.who.int/iris/handle/10665/39473.
29. Andrade SE, Kahler KH, Frech F, et al. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 2006;15(8):565-74.
30. Jackson CA, Clatworthy J, Robinson A, et al. Factors Associated With Non-Adherence to Oral Medication for Inflammatory Bowel Disease: A Systematic Review. Am J Gastroenterol 2009;105(3):525-39.
31. Ballester MP, Marti-Aguado D, Fullana M, et al. Impact and risk factors of non-adherence to 5-aminosalicylates in quiescent ulcerative colitis evaluated by an electronic management system. Int J Colorectal Dis 2019;34(6):1053-9.
32. Marti-Aguado D, Ballester MP, Tosca J, et al. Long-term follow-up of patients treated with aminosalicylates for ulcerative colitis: Predictive factors of response: An observational case-control study. United European Gastroenterol J 2019;7(8):1042-50.
33. Tae CH, Jung S-A, Moon HS, et al. Importance of Patients’ Knowledge of Their Prescribed Medication in Improving Treatment Adherence in Inflammatory Bowel Disease. J Clin Gastroenterol 2016;50(2):157-62.
Related articles

Letter

Broadening perspectives in the treatment of chronic pouchitis

DOI: 10.17235/reed.2024.10865/2024

Letter

Tofacitinib-induced eosinophilia

DOI: 10.17235/reed.2023.9831/2023

Letter

Perianal Paget’s disease

DOI: 10.17235/reed.2022.9304/2022

Letter

Chinese dragon sign of ulcerative colitis

DOI: 10.17235/reed.2022.9154/2022

Letter

Ulcerative colitis exacerbated by strongyloidiasis

DOI: 10.17235/reed.2022.9044/2022

Review

Clinical settings with tofacitinib in ulcerative colitis

DOI: 10.17235/reed.2022.8660/2022

Letter

Mesalazine induced interstitial pneumonitis in the COVID era

DOI: 10.17235/reed.2022.8635/2021

Letter

The effect of Adacolumn® on ulcerative colitis with COVID-19

DOI: 10.17235/reed.2020.7156/2020

Letter

Sweet syndrome in severe ulcerative flare

DOI: 10.17235/reed.2020.6995/2020

Letter to the Editor

Ulcerative colitis with gastric and duodenal involvement

DOI: 10.17235/reed.2017.4685/2016

Editorial

Specialist care in the management of inflammatory bowel disease

DOI: 10.17235/reed.2016.4628/2016

Original

Mercaptopurine and inflammatory bowel disease: the other thiopurine

DOI: 10.17235/reed.2016.4546/2016

Case Report

Mesalamine-induced myopericarditis - A case report

DOI: 10.17235/reed.2016.4016/2015

Citation tools
Gómez-Medina C, Capilla-Lozano M, Ballester-Ferré M, Martí-Aguado D, Crespo A, Bosca-Watts M, et all. Thiopurine adherence: a high prevalence with low impact on UC outcomes . 7630/2020


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 1256 visits.
This article has been downloaded 126 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 02/11/2020

Accepted: 08/03/2021

Online First: 18/03/2021

Published: 07/02/2022

Article revision time: 120 days

Article Online First time: 136 days

Article editing time: 462 days


Share
This article has been rated by 1 readers.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2024 y Creative Commons. The Spanish Journal of Gastroenterology